Fibromyalgia is real, biologically grounded, and increasingly mechanism-understood. This page exists to help you and your advocates prepare for appointments, ask the right questions, and find authoritative information about diagnosis, treatment, and the science moving the field forward. It is advocacy, not medical advice — every recommendation here is something to consider raising with your healthcare team, never a substitute for individualized clinical care.
Many patients with fibromyalgia have experienced a clinician dismissing their symptoms, a family member doubting them, an insurance company denying coverage, or an employer or disability adjudicator treating the diagnosis as suspect. This is real, it is documented, and it is one of the structural problems the field is — slowly — addressing.
The 2016 ACR criteria explicitly removed the "diagnosis of exclusion" framing. The 2025 GWAS data establishes FM at the population genetic level as a CNS disorder. The autoantibody passive-transfer evidence shows FM-like pain can be transmitted to mice via patient blood — biology, not psychology. Objective biomarker research is producing measurable findings that no longer depend on subjective interpretation.
None of this resolves the lived experience of being doubted. But each piece of evidence makes the case harder to dismiss. The questions in this page exist in part to help you push back from a position of information rather than frustration. If a clinician dismisses fibromyalgia as "not real" or "all in your head," that is not consistent with current medical evidence — and you have the option of finding a different clinician or asking for a referral to one with current training in chronic pain or rheumatology.
The research priority page of this project — mechanism — describes what's known about the underlying biology. It is written for researchers, but if you want to see what the evidence actually says, that's where it is.
Fibromyalgia has historically carried a diagnostic stigma that is unique among chronic illnesses of comparable prevalence. The science of the last decade — mechanism subtypes, autoantibody passive-transfer evidence, brain-tissue heritability data, emerging objective biomarkers — is changing that picture. But change takes time at the clinical bedside, and in the meantime, patients still encounter dismissive clinicians, skeptical family members, and insurance and disability systems that don't always recognize the condition for what it is. Being informed is your most reliable lever.
This page is structured as a set of questions to consider asking, conditions worth being aware of, and resources you can trust. It does not prescribe a workup, recommend a specific medication, or substitute for individualized medical care. Decisions belong to you and your healthcare team. The most useful thing this page can offer is helping you arrive at those decisions prepared.
Throughout, links go to authoritative sources — government health agencies, professional medical societies, and established patient organizations. We don't link to commercial pages, supplement sellers, or sites without clear editorial accountability.
There is no single blood test or scan that diagnoses fibromyalgia. The current standard is the 2016 American College of Rheumatology criteria, which uses a structured symptom assessment.
A count of body regions where pain has been experienced over the past week, scored 0–19. The threshold is WPI ≥ 7 (or WPI 4–6 with a high SSS score).
A 0–12 score capturing fatigue, unrefreshing sleep, cognitive symptoms, headaches, abdominal pain, and mood. Threshold is SSS ≥ 5 (paired with high WPI) or SSS ≥ 9.
Pain present in at least 4 of 5 body regions, sustained at similar levels for ≥ 3 months. This distinguishes generalized FM from regional pain syndromes.
The 2016 revision removed the requirement that fibromyalgia can only be diagnosed after ruling out everything else. Today, a fibromyalgia diagnosis can be made independently of other diagnoses — you can have fibromyalgia and rheumatoid arthritis, fibromyalgia and Sjögren's syndrome, fibromyalgia and hypothyroidism. This matters because the old "diagnosis of exclusion" framing was a major driver of diagnostic delay and dismissal.
This does not mean other conditions shouldn't be evaluated. A proper workup should still look for treatable contributors and overlapping diagnoses. But a clinician who tells you "you can't have fibromyalgia because we haven't ruled out everything else" is working from out-of-date criteria.
References: 2016 ACR FM criteria (full text) · Wolfe et al 2016 revision paper · Printable diagnostic form (Bateman Horne Center)
These are questions worth raising with the clinician evaluating you — typically a primary care physician or a rheumatologist. Not every question applies to every patient, but each one represents a decision point that should at least be discussed and documented in your chart.
A reasonable workup considers — and where appropriate, screens for — other conditions that can cause widespread pain, fatigue, or cognitive symptoms. Standard tests typically include:
Questions to ask:
Roughly 40–60% of fibromyalgia patients show reduced small-nerve-fiber density on skin biopsy or corneal confocal microscopy. This is a real, measurable biological finding — small-fiber neuropathy (SFN) is one of the recognized subtypes within FM. If you have prominent burning, tingling, or autonomic symptoms (sweating changes, GI dysmotility, orthostatic intolerance), this is worth raising:
Unrefreshing sleep is one of the most consistent features of fibromyalgia and a documented mechanism contributor (alpha-wave intrusion into deep sleep is an established FM finding). Untreated obstructive sleep apnea is common, treatable, and frequently amplifies FM symptoms.
Both major medical society guidelines — EULAR (European) and NIAMS (U.S.) — recommend a combination of non-pharmacological and pharmacological approaches, prioritized to the individual patient. Treatment is a conversation, not a recipe.
As of 2025, four medications have been FDA-approved specifically for fibromyalgia:
Other medications are sometimes used off-label (gabapentin, low-dose naltrexone, amitriptyline, tramadol). Off-label is not the same as unsupported — it just means the medication wasn't formally tested and approved for FM.
Questions to ask:
EULAR's guidelines explicitly prioritize non-pharmacological treatment as first-line. The strongest-evidence approaches include:
Questions to ask:
The most consequential thing many patients can do is arrive prepared. Specifics travel better than generalities — a documented symptom log carries more weight than a remembered impression.
A one-page document with: symptom onset, what makes things better/worse, current and prior treatments tried, what worked / what didn't, current medications, and your top 2–3 questions for this visit.
Take notes. Ask the clinician to repeat important points. Ask them to write the recommendations in your chart and provide an after-visit summary. "Can you put that in writing for me?" is a reasonable request.
Keep a brief symptom log between visits. Note what you tried, when, and what changed. A 5-week trial of a medication is more meaningful when you can show specifically what changed week by week.
Fibromyalgia is a recognized disability under the Americans with Disabilities Act when it substantially limits major life activities. Disability claims and insurance documentation require specific, repeated, documented evidence over time. If this is or may become part of your situation:
It is honest to say that the picture of fibromyalgia in 2026 is meaningfully different from the picture in 2010. The field is moving from "diagnosis of exclusion" toward "subtype-stratified mechanism-based condition" with emerging objective biomarkers. None of this has yet reached routine clinical practice — but it is the direction the science is going, and being informed about it is part of being your own advocate.
One of this project's current research priorities is whether retinal imaging — optical coherence tomography (OCT), OCT angiography, and corneal confocal microscopy — can serve as a non-invasive, multi-mechanism biomarker for fibromyalgia. The retina is embryologically central nervous system tissue, and several FM-relevant findings are detectable there: retinal nerve fiber layer thinning, microvascular changes, choroidal thickness alterations, and reduced corneal nerve fiber density. A clinical-grade imaging panel of this kind would address both the scientific gap (a low-cost multi-chain biomarker) and the clinical-political gap (an objective measurement that supports diagnostic legitimacy).
This is research, not standard care. We mention it here because patients ask, and because it's the kind of work the community has been waiting on. See the mechanism page for the underlying science.
The following are established, accountable, mostly free resources. Government agencies, professional medical societies, and patient organizations with transparent governance. We omit commercial sites and supplement vendors. Inclusion here is not an endorsement of any particular recommendation those sites make — it's a marker that they meet a baseline accountability standard.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is the primary U.S. federal agency for FM research and patient information.
NIAMS fibromyalgia page →NIH's National Center for Complementary and Integrative Health publishes evidence-based summaries of non-pharmacological approaches relevant to FM.
NCCIH fibromyalgia in-depth →NIH's consumer-focused health information service. Plain-language summaries and curated link collections.
MedlinePlus FM page →The Centers for Disease Control and Prevention maintains a fibromyalgia overview within its chronic-disease resources.
CDC fibromyalgia →The U.S. rheumatology professional society. Publishes the diagnostic criteria, position statements, and patient-facing materials.
ACR patient resources →The European League Against Rheumatism publishes the leading international FM management guidelines, periodically updated.
EULAR FM guidelines →Mayo Clinic's patient-facing fibromyalgia page is a widely-used, regularly-updated, editorially-accountable overview of symptoms, diagnosis, and treatment.
Mayo Clinic FM page →Companion overview from Cleveland Clinic with practical patient-facing detail on symptoms, workup, and treatment options.
Cleveland Clinic FM page →An open-access clinical reference used by physicians and trainees. More technical but rigorous; useful for advocates who want clinical-level detail.
StatPearls fibromyalgia →A nonprofit clinical and research center focused on fibromyalgia and ME/CFS. Particularly useful for patients with overlapping conditions; publishes practical clinical resources.
Bateman Horne Center →Long-standing U.S. patient organization. Publishes the "Fibromyalgia AWARE" magazine and maintains current information for newly diagnosed patients.
FMAware (NFA) →U.S. nonprofit advocacy organization; funds peer-reviewed FM research and publishes patient-facing material on diagnosis and treatment options.
AFSA →U.S. nonprofit covering arthritis and adjacent musculoskeletal conditions including fibromyalgia. Useful for patients with overlapping joint disease.
Arthritis Foundation FM →The U.S. federal registry of clinical trials. Search "fibromyalgia" or specific drugs/interventions; each entry lists eligibility criteria and contact information.
FM clinical trials →For patients with ME/CFS overlap. Particularly relevant given the substantial mechanistic overlap between FM and ME/CFS and the shared post-infectious onset pattern.
#MEAction →Nonprofit funding research into ME/CFS, long COVID, and post-infectious syndromes — the conditions most mechanistically adjacent to fibromyalgia.
Open Medicine Foundation →SSR 12-2p formally recognizes fibromyalgia as a medically determinable impairment for Social Security disability evaluation. Useful for patients pursuing SSDI claims.
SSA SSR 12-2p →The Department of Veterans Affairs publishes a fibromyalgia patient fact sheet; FM is a recognized presumptive condition for certain veterans under specific circumstances.
VA fibromyalgia fact sheet →